BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24040035)

  • 21. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
    Vangala JR; Dudem S; Jain N; Kalivendi SV
    J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer.
    Son B; Jun SY; Seo H; Youn H; Yang HJ; Kim W; Kim HK; Kang C; Youn B
    Sci Rep; 2016 Feb; 6():21986. PubMed ID: 26906215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of PF-02341066 and radiation on non-small cell lung cancer cells.
    Tumati V; Kumar S; Yu L; Chen B; Choy H; Saha D
    Oncol Rep; 2013 Mar; 29(3):1094-100. PubMed ID: 23254764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
    Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
    Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BU-32: a novel proteasome inhibitor for breast cancer.
    Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
    Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
    Zismanov V; Drucker L; Gottfried M
    Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.
    Voortman J; Checińska A; Giaccone G
    Mol Cancer; 2007 Nov; 6():73. PubMed ID: 18021420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
    Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
    J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
    Momose I; Tatsuda D; Ohba S; Masuda T; Ikeda D; Nomoto A
    Cancer Sci; 2012 Sep; 103(9):1730-6. PubMed ID: 22676179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
    Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional validation of miRNAs targeting genes of DNA double-strand break repair to radiosensitize non-small lung cancer cells.
    Piotto C; Biscontin A; Millino C; Mognato M
    Biochim Biophys Acta Gene Regul Mech; 2018 Dec; 1861(12):1102-1118. PubMed ID: 30389599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.
    Kang J; Kim E; Kim W; Seong KM; Youn H; Kim JW; Kim J; Youn B
    J Biol Chem; 2013 Sep; 288(38):27343-27357. PubMed ID: 23902763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.